Glauprost, eye drops 0.005% 2.5ml

Antiglaucoma drug. Prostaglandin F2α analogue and selective FP-receptor agonist. Reduces intraocular pressure by increasing aqueous humor outflow, mainly via uveoscleral pathway, as well as through trabecular meshwork. Does not reliably affect aqueous humor production and does not affect the blood-ophthalmic barrier. Decrease of intraocular pressure starts 3-4 hours after injection of the drug; the maximum effect is registered after 8-12 hours; the action lasts for at least 24 hours.

Pharmacokinetics

It penetrates well through the cornea with hydrolysis to the biologically active form. Time of reaching maximum concentration (TC mah ) in aqueous humor is 2 hours after topical application.

Latanoprost acid is practically not metabolized in the eye tissues; metabolism occurs mainly in the liver. The elimination half-life (T 1/2 ) is 17 min. The main metabolites – 1,2-dinor- and 1,2,3,4-tetranormetabodites have no or little biological activity.

Extracted by the kidneys.

< br>.

Indications

Open-angle glaucoma and elevated intraocular pressure.

Active ingredient

Composition

1 ml – latanoprost 50 mcg

Associated substances:

dodecahydrate disodium hydrophosphate,

sodium dihydrophosphate dihydrate,

How to take, the dosage

In the conjunctival sac of the affected eye, 1 drop once daily, in the evening.

If a dose is missed, the next dose is not doubled and is given as usual.

Interaction

Pharmaceutically incompatible with eye drops containing thiomersal precipitate.

The simultaneous injection of two prostaglandin analogues may cause a paradoxical increase in intraocular pressure.

If combined therapy is prescribed, eye drops of different medications should be administered at least 5 min apart.

Special Instructions

Causes a gradual change in eye color by increasing the amount of brown pigment in the iris. This effect is predominantly seen in patients with mixed iris coloration, such as blue-brown, gray-brown, green-brown, or yellow-brown, due to increased melanin content in the stromal melanocytes of the iris. Brown pigmentation usually spreads concentrically around the pupil to the periphery of the iris of the eye, and the entire iris or parts of it may become more intense brown. If there is an intense change in ocular pigmentation, therapy should be discontinued.

In patients with uniformly blue, gray, green or brown colored eyes, changes in eye color after 2 years of use are very rare. The color change that develops may be irreversible. Patients should be informed of the possibility of eye color change before treatment.

The drug contains benzalkonium chloride which may be absorbed by contact lenses. Contact lenses should be removed before applying the eye drops; lenses should not be inserted until 15 minutes after application.

Latanoprost may cause gradual changes in eyelashes and down hair, such as lengthening, thickening, increasing pigmentation, increasing density, and changing the direction of eyelash growth. Eyelash changes are reversible and go away after treatment is discontinued.

In patients using drops in only one eye, heterochromia may develop.

Impact on driving and operating machinery

Patients who experience transient blurring of vision after use of eye drops are not recommended to drive vehicles or operate machinery until it is restored.

Contraindications

With caution, the drug should be used in patients with aphakia, pseudoaphakia with rupture of the posterior lens capsule, in patients with known risk factors of macular edema (cases of macular edema, including cystoid edema, have been described during treatment with latanoprost.including cystoid), in patients with inflammatory, neovascular or congenital glaucoma (due to insufficient experience with the drug).

Side effects

Eye irritation (itching, burning sensation, sensation of sand in the eye, tingling and sensation of foreign body), eye pain, blepharitis, conjunctival hyperemia, eyelid edema, corneal edema and erosions, increased iris pigmentation, transient pinpoint epithelial erosions, conjunctivitis; lengthening, thickening, increase in number and pigmentation of eyelashes and downy hair, change in direction of eyelash growth, sometimes causing eye irritation, blurred vision, iritis/veitis, keratitis, macular edema (incl.including cystoid),.

Respiratory system disorders Bronchial asthma (including acute attacks or exacerbation of the disease in patients with a history of bronchial asthma), dyspnea. Dermatological reactions Rash, darkening of the eyelid skin and local skin reactions on the side of the eyelids.

Muscular system disorders Muscle pain, joint pain.

Nervous system disorders Dizziness, headache. Other Non-specific chest pain.

Overdose

Symptoms: irritation of the mucous membrane of the eye, hyperemia of the conjunctiva or episclera.

Treatment: symptomatic.

Pregnancy use

The drug Glauprost is contraindicated in children (under 18 years of age).

The use of Glauprost during pregnancy is only possible under medical supervision and only if the expected benefits to the mother outweigh the risk of possible side effects in the fetus.

Latanoprost and its metabolites may be excreted with the breast milk. Breastfeeding should be stopped if Glauprost must be prescribed during lactation.

Similarities